Paul Bisaro

Paul M. Bisaro brings deep operational and strategic insight to the Board, with more than 30 years of business, management, and leadership experience in the pharmaceutical industry. He served as Chairman of the Board of Directors for Mallinckrodt from February 2024 to July 2025 and from June 2022 to November 2023.

Mr. Bisaro currently serves on the boards of Pleo Pharma, Zoetis Inc., and Myriad Genetics, Inc., having joined in April 2020, May 2015, and October 2022, respectively. Past board service includes TherapeuticsMD (2020–2022) and Zimmer Biomet Holdings, Inc. (2013–2017). His executive experience spans roles such as Executive Chairman at Amneal Pharmaceuticals, Inc. (2018–2019) and Allergan (2014–2016), as well as CEO positions at Actavis plc (formerly Watson Pharmaceuticals) and Impax Laboratories.

Mr. Bisaro earned an undergraduate degree from the University of Michigan and a Juris Doctor from the Catholic University of America.